Centaurus Financial Inc. boosted its stake in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 9.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,128 shares of the medical research company’s stock after buying an additional 189 shares during the quarter. Centaurus Financial Inc.’s holdings in Amgen were worth $480,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of AMGN. FMR LLC lifted its holdings in Amgen by 24.9% in the second quarter. FMR LLC now owns 8,911,384 shares of the medical research company’s stock worth $2,168,140,000 after buying an additional 1,774,223 shares during the period. Vanguard Group Inc. lifted its holdings in Amgen by 2.8% in the third quarter. Vanguard Group Inc. now owns 47,459,511 shares of the medical research company’s stock worth $10,697,373,000 after buying an additional 1,310,894 shares during the period. Renaissance Technologies LLC lifted its holdings in Amgen by 279.3% in the second quarter. Renaissance Technologies LLC now owns 1,439,745 shares of the medical research company’s stock worth $350,290,000 after buying an additional 1,060,200 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Amgen by 164.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,337,970 shares of the medical research company’s stock worth $323,548,000 after buying an additional 832,885 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in Amgen by 84.5% in the third quarter. Robeco Institutional Asset Management B.V. now owns 1,201,655 shares of the medical research company’s stock worth $270,853,000 after buying an additional 550,439 shares during the period. 75.53% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Price Performance
Shares of AMGN opened at $229.79 on Friday. The company has a market capitalization of $122.70 billion, a P/E ratio of 18.98, a price-to-earnings-growth ratio of 1.86 and a beta of 0.65. The company has a quick ratio of 1.10, a current ratio of 1.41 and a debt-to-equity ratio of 10.20. The firm has a 50 day moving average of $245.91 and a 200 day moving average of $254.71. Amgen Inc. has a twelve month low of $223.30 and a twelve month high of $296.67.
Amgen Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be given a $2.13 dividend. This represents a $8.52 dividend on an annualized basis and a yield of 3.71%. The ex-dividend date of this dividend is Wednesday, May 17th. Amgen’s dividend payout ratio (DPR) is presently 70.36%.
Analyst Upgrades and Downgrades
AMGN has been the subject of several research analyst reports. BMO Capital Markets lowered their price objective on shares of Amgen from $276.00 to $253.00 and set a “market perform” rating for the company in a report on Wednesday, February 1st. SVB Securities lowered their target price on shares of Amgen from $282.00 to $267.00 in a report on Thursday, February 2nd. Cowen lowered their target price on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. StockNews.com assumed coverage on shares of Amgen in a report on Thursday. They set a “strong-buy” rating for the company. Finally, Credit Suisse Group lowered their target price on shares of Amgen from $240.00 to $220.00 and set an “underperform” rating for the company in a report on Wednesday, February 1st. Four research analysts have rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average target price of $251.44.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Get Rating).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.